E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/28/2006 in the Prospect News Biotech Daily.

QLT rated at sector perform by RBC

RBC Capital Markets analyst Douglas Miehm rated QLT Inc. at sector perform, above average risk, after the company reported second-quarter results. GAAP earnings per share of $0.09 were below the analyst's and consensus of $0.12. Total revenues for the quarter declined to $47.8 million from $59.6 million in the same period last year. QLT lowered its guidance to the range of $370 million to $385 million from $370 million to $400 million originally. Shares of the Vancouver, B.C.-based biopharmaceutical company were down 12 cents, or 1.68%, at $7.03 on volume of 1,036,373 shares versus the three-month running average of 762,080 shares. (Nasdaq: QLTI)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.